IREN Limited stock: what Monday looks like after a $50 swing and bitcoin back near $90,000

IREN Limited stock: what Monday looks like after a $50 swing and bitcoin back near $90,000

New York, Jan 11, 2026, 18:13 EST — Market closed

  • IREN closed Friday 0.7% higher at $46.03, following a volatile session.
  • Bitcoin stayed close to $90,000, keeping crypto-related stocks in the spotlight on Monday.
  • Traders are focused on how AI buildouts are progressing and eyeing the upcoming earnings window for fresh details on funding and timelines. (Nasdaq)

IREN Limited shares ended Friday up 0.7% at $46.03, swinging between a high near $50 and a low of $45.52 amid heavy volume in a choppy session. With U.S. markets closed Sunday, the stock is poised for a new test when trading picks up again Monday.

The move is significant since IREN is caught up in two high-velocity trades simultaneously: bitcoin-linked miners and the expansion of power-hungry data centers for artificial intelligence. When either trend pivots, the stock reacts sharply—and not always predictably.

That’s the scene as the week kicks off. Investors are wrestling with valuing a business still tied to bitcoin, while it pours cash into boosting AI capabilities. Cash flow and timing are now front and center in every discussion.

Bitcoin hovered near $90,371, holding steady on the day. Stocks tied to crypto and data centers showed mixed moves Friday: Applied Digital surged roughly 18%, Hut 8 climbed about 3.6%, Riot Platforms ticked up 1.3%, and Marathon Digital edged down 2.0%.

IREN is banking on a long-term AI cloud deal with Microsoft, pegged at around $9.7 billion and featuring a 20% upfront payment. According to the company, the agreement involves rolling out NVIDIA GB300 GPUs—key chips for AI model training and operation—at its Childress, Texas site in stages through 2026. The project includes building new liquid-cooled data centers designed to handle 200 megawatts of “IT load,” which represents the actual power servers consume. (IREN)

Co-CEO Daniel Roberts described the deal as a “milestone partnership with Microsoft.” Jonathan Tinter, a Microsoft executive, said the collaboration is “delivering cutting-edge AI infrastructure for our customers.” (GlobeNewswire)

Execution remains the toughest challenge. Reuters reported that the Microsoft deal includes strict delivery timelines, with the agreement subject to termination if IREN misses them. This underscores that the deal hinges not only on AI chip demand but also on delivering at scale and on schedule. (Reuters)

That raises another key question investors are focused on: funding. IREN says it plans to cover capital spending linked to the contract using existing cash, customer prepayments, operating cash flow, and some additional financing moves. (IREN)

Nasdaq’s earnings calendar currently points to IREN reporting around Feb. 11, but the company hasn’t locked in a date yet. Investors will be focused on any news about deployment schedules, spending forecasts, and shifts in revenue growth as new capacity kicks in. (Nasdaq)

But the downside case is straightforward: bitcoin dips, risk appetite wanes, and the stock’s “AI data center” premium comes under pressure if financing costs climb or construction delays hit. Another volatile swing like Friday’s—surging toward $50 before retreating—would catch few shorts or momentum traders off guard.

Monday’s session boils down to one key focus: how bitcoin behaves near the $90,000 mark and if the wider crypto and AI-infrastructure stocks hold their ground. Keep an eye on mid-February earnings, too—when IREN must deliver updated figures and timelines to back its narrative.

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
Fiserv stock in focus: what to watch as FISV heads into Monday after “Unknown Shopper” launch
Previous Story

Fiserv stock in focus: what to watch as FISV heads into Monday after “Unknown Shopper” launch

Opendoor stock jumps on Trump’s $200 billion mortgage-bond plan — what to know before Monday
Next Story

Opendoor stock jumps on Trump’s $200 billion mortgage-bond plan — what to know before Monday

Go toTop